Literature DB >> 16001449

Expression and role of Foxa proteins in prostate cancer.

Janni Mirosevich1, Nan Gao, Aparna Gupta, Scott B Shappell, Richard Jove, Robert J Matusik.   

Abstract

The molecular mechanism(s) for prostate cancer progression to androgen independence are poorly understood. We have recently shown that Foxa1 and Foxa2 proteins are differentially expressed in epithelial cells during murine prostate development, growth, and adult function. Currently, the role of Foxa proteins in prostate cancer development and progression is unknown. Foxa protein expression was investigated in the LPB-Tag LADY mouse prostate cancer models, in human prostate cancer specimens, and various prostate cancer cell lines using Western blot and immunostaining analysis. In vitro transient transfection, studies were performed to investigate Foxa/prostate-specific gene regulation. Foxa1 was strongly expressed in areas of prostatic intraepithelial neoplasia (PIN) in both the androgen dependent 12T-7f and in the metastatic, androgen independent 12T-10 LADY models. Prominent Foxa1 and Foxa2 expression was observed in 12T-10 invasive undifferentiated neuroendocrine carcinomas, in the hormone independent and metastasizing 12T-10 derived, NE-10 allograft tumors, and in all metastatic lesions isolated from 12T-10 mice. Foxa1 protein expression was always observed in human prostate carcinomas, regardless of Gleason grade score, while Foxa2 was only detected in neuroendocrine small cell carcinomas and in some high Gleason score adenocarcinomas. Foxa proteins were also differentially expressed in three prostate cancer cell lines. Importantly, in vitro functional assays demonstrated that Foxa2 could activate androgen-dependent prostate-specific genes in an androgen receptor and ligand-independent manner. These results suggest that Foxa proteins are important in prostate carcinogenesis. In particular, Foxa2 may be involved in progression of prostate cancer to androgen independence. As such, Foxa proteins may represent novel targets for therapeutic intervention. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16001449     DOI: 10.1002/pros.20299

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  70 in total

1.  Foxa2 activates the transcription of androgen receptor target genes in castrate resistant prostatic tumors.

Authors:  Zachary M Connelly; Shu Yang; Fenghua Chen; Yunshin Yeh; Nazih Khater; Renjie Jin; Robert Matusik; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2018-10-20

Review 2.  FOXA1: master of steroid receptor function in cancer.

Authors:  Michael A Augello; Theresa E Hickey; Karen E Knudsen
Journal:  EMBO J       Date:  2011-09-20       Impact factor: 11.598

3.  Bioinformatics analyses of publicly available NEPCa datasets.

Authors:  Siyuan Cheng; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

4.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

5.  A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland.

Authors:  Ryan P McMullin; Albert Dobi; Laura N Mutton; András Orosz; Shilpi Maheshwari; Cooduvalli S Shashikant; Charles J Bieberich
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

Review 6.  Exploring the origins of the normal prostate and prostate cancer stem cell.

Authors:  Susan Kasper
Journal:  Stem Cell Rev       Date:  2008-09       Impact factor: 5.739

7.  NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.

Authors:  Magdalena M Grabowska; Amicia D Elliott; David J DeGraff; Philip D Anderson; Govindaraj Anumanthan; Hironobu Yamashita; Qian Sun; David B Friedman; David L Hachey; Xiuping Yu; Jonathan H Sheehan; Jung-Mo Ahn; Ganesh V Raj; David W Piston; Richard M Gronostajski; Robert J Matusik
Journal:  Mol Endocrinol       Date:  2014-05-06

Review 8.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

9.  Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.

Authors:  X-B Shi; L Xue; A-H Ma; C G Tepper; R Gandour-Edwards; H-J Kung; R W deVere White
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

10.  Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.

Authors:  Aparna Gupta; Xiuping Yu; Tom Case; Manik Paul; Michael M Shen; Klaus H Kaestner; Robert J Matusik
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.